Scopus Biopharma Valuation
| SCPSDelisted Stock | USD 0.10 0.00 0.00% |
Scopus Biopharma seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Scopus Biopharma from inspecting the company fundamentals such as Shares Owned By Institutions of 2.15 %, shares outstanding of 21.09 M, and Return On Equity of -15.6 as well as reviewing its technical indicators and probability of bankruptcy. . In general, most investors recommend acquiring undervalued stocks and selling overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
Overvalued
Today
Please note that Scopus Biopharma's price fluctuation is very steady at this time. Calculation of the real value of Scopus Biopharma is based on 3 months time horizon. Increasing Scopus Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Scopus otc stock is determined by what a typical buyer is willing to pay for full or partial control of Scopus Biopharma. Since Scopus Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Scopus OTC Stock. However, Scopus Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.1 | Real 0.095 | Hype 0.1 |
The intrinsic value of Scopus Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Scopus Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Scopus Biopharma helps investors to forecast how Scopus otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Scopus Biopharma more accurately as focusing exclusively on Scopus Biopharma's fundamentals will not take into account other important factors: Scopus Biopharma Total Value Analysis
Scopus Biopharma is at this time projected to have valuation of 1.18 M with market capitalization of 2.17 M, debt of 2.54 M, and cash on hands of 1.16 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Scopus Biopharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.18 M | 2.17 M | 2.54 M | 1.16 M |
Scopus Biopharma Asset Utilization
One of the ways to look at asset utilization of Scopus is to check how much profit was generated for every dollar of assets it reports. Scopus Biopharma has a negative utilization of assets of -4.61 %, losing $0.0461 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Scopus Biopharma shows how discouraging it operates for each dollar spent on its assets.Scopus Biopharma Ownership Allocation
Scopus Biopharma shows a total of 21.09 Million outstanding shares. Scopus Biopharma maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Scopus Biopharma Profitability Analysis
Net Loss for the year was (26.95 M) with profit before overhead, payroll, taxes, and interest of 0.About Scopus Biopharma Valuation
The otc valuation mechanism determines Scopus Biopharma's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Scopus Biopharma based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Scopus Biopharma. We calculate exposure to Scopus Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Scopus Biopharma's related companies.Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York. Scopus Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.
8 Steps to conduct Scopus Biopharma's Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Scopus Biopharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Scopus Biopharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Scopus Biopharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Scopus Biopharma's revenue streams: Identify Scopus Biopharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Scopus Biopharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Scopus Biopharma's growth potential: Evaluate Scopus Biopharma's management, business model, and growth potential.
- Determine Scopus Biopharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Scopus Biopharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Scopus Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Scopus Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 13.4 M | |
| Retained Earnings | -41.5 M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |